Kaiser Permanente EMR Integration goes live

15 November 2023
KAISER PERMANENTE EMR INTEGRATION GOES LIVE
DUNEDIN, New Zealand – Cancer diagnostics company Pacific Edge (NZX, ASX: PEB)
announces the launch of the integration of Cxbladder tests within the Electronic Medical
Records (EMR) system of Kaiser Permanente.
The integration, which has gone live within all 15 urology medical centers of the Southern
California Permanente Medical Group (Kaiser Permanente SoCal), is a significant
improvement to patient access for Cxbladder with sample collection at Kaiser facilities and
offers electronic management of test ordering and resulting for simpler patient care.
Starting today, Kaiser Permanente urologists can now electronically order Cxbladder Triage
for patients referred for hematuria evaluation and Cxbladder Monitor for those under
surveillance for the recurrence of bladder cancer, according to a standardized clinical pathway
agreed by Kaiser Permanente SoCal’s Urology Section Chiefs. Results are returned directly to
a patient’s EMR.
Following a test ordered through the EMR, patients will be able to have their urine samples
collected at 29 separate facilities where Kaiser Permanente staff are being trained on sample
collection and stabilization to ensure samples received in the lab are of the highest quality.
Additionally, Cxbladder urine collection kits will be stored at each of these facilities and
managed by site-specific logistics and restocking processes to optimize needs-based
availability of Cxbladder kits for optimized operations.
Kaiser Permanente is the largest integrated healthcare provider in the US, serving 12.6 million
members, which equates to approximately 3.7% of the population. Kaiser Permanente’s
Southern California region is the largest region by membership and manages the care for
approximately 37% of all patients managed by the health plan. In aggregate Kaiser
Permanente SoCal’s urology team conducts ~25,000 cystoscopies each year across the
relevant hematuria evaluation and bladder cancer surveillance clinical pathways.
The integration of Cxbladder into these pathways, according to a Kaiser Permanente study,
could allow the organization to safely avoid more than 70% of these examinations, saving
money and sparing patients from the risks and discomfort of the invasive procedure
1
.
Pacific Edge Chief Executive Dr Peter Meintjes says: “We are excited to have completed this
important partnership together with Kaiser Permanente – a project that spanned many teams
and many person-hours across the Kaiser system, our team in the US, and our team in New
Zealand. The patients of Kaiser Permanente SoCal will be among the first in the US to benefit
from a standardized clinical approach to hematuria evaluation and monitoring for the
recurrence of bladder cancer.”

1
AUA, LUGPA, AACU Joint Response to Novitas DL 39365

Dr Meintjes noted that this milestone indicates the commitment to a standard clinical pathway
and represents a significant opportunity to optimize the evaluation and management of bladder
cancer.
Dr Eugene Rhee, MD MBA, National Chair of Urology for Kaiser Permanente and Regional
Chief of Urology for The Southern California Permanente Medical Group, said Cxbladder tests
have greatly improved Kaiser Permanente’s ability to safely work up and provide surveillance
to a highly vulnerable population of patients.
“In addition, these tests have improved access to urology care. The very high negative
predictive value of the Cxbladder tests have allowed us to improve access by safely reducing
overwhelming demand for hematuria evaluation and surveillance cystoscopy. It’s proven to be
a quadruple win: convenient and preferred by our members, high quality - reliable results,
adding additional capacity for the organization, and a sustainable way to improve the wellbeing
of our healthcare teams," Dr Rhee said.
“For our members this means fewer invasive, uncomfortable, and time-consuming
cystoscopies and timely and efficient diagnosis. With the system integration complete we are
now well positioned to roll out Cxbladder tests across our network. We are delighted with the
way the Kaiser Permanente and Pacific Edge teams have worked together and look forward
to building on this relationship in the future.”
Released for an on behalf of Pacific Edge by Grant Gibson, Chief Financial Officer.
For more information:
Investors: Media:
Dr Peter Meintjes Richard Inder
Chief Executive The Project
Pacific Edge P: +64 21 645 643
P: 022 032 1263
OVERVIEW
Pacific Edge: www.pacificedgedx.com
Pacific Edge Limited (NZX/ ASX: PEB) is a global cancer diagnostics company leading the way
in the development and commercialization of bladder cancer diagnostic and prognostic tests
for patients presenting with hematuria or surveillance of recurrent disease. Headquartered in
Dunedin, New Zealand, the company provides its suite of Cxbladder tests globally through its
wholly owned, and CLIA certified, laboratories in New Zealand and the USA.
Cxbladder: www.cxbladder.com
Cxbladder is a urine-based genomic biomarker test optimized for the detection and surveillance
of bladder cancer. The Cxbladder evidence portfolio developed over the past 14 years includes
more than 20 peer reviewed publications for primary detection, surveillance, adjudication of
atypical urine cytology and equivocal cystoscopy. Cxbladder is the focal point of numerous

ongoing and planned clinical studies to generate an ever-increasing body of clinical utility
evidence supporting adoption and use in the clinic to improve patient health outcomes.
Cxbladder has been trusted by over 4,400 US urologists in the diagnosis and management of
more than 100,000 patients, including the option for in-home sample collection. In New
Zealand, Cxbladder is accessible to 75% of the population via public healthcare and all
residents have the option of buying the test online.